nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—Neurological symptom—Cisplatin—bone cancer	0.0302	0.0561	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—CYP4V2—bone cancer	0.0247	0.0535	CbGpPWpGaD
Ezogabine—UGT1A1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.02	0.0435	CbGpPWpGaD
Ezogabine—UGT1A4—Tamoxifen metabolism—CYP3A4—bone cancer	0.0161	0.035	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0154	0.0334	CbGpPWpGaD
Ezogabine—UGT1A3—Estrogen metabolism—CYP3A4—bone cancer	0.0152	0.0329	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP4V2—bone cancer	0.015	0.0324	CbGpPWpGaD
Ezogabine—UGT1A1—Irinotecan Pathway—CYP3A4—bone cancer	0.0128	0.0278	CbGpPWpGaD
Ezogabine—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.0128	0.0278	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP4V2—bone cancer	0.0124	0.027	CbGpPWpGaD
Ezogabine—UGT1A4—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.0115	0.025	CbGpPWpGaD
Ezogabine—Infection—Carboplatin—bone cancer	0.011	0.0205	CcSEcCtD
Ezogabine—Raised liver function tests—Methotrexate—bone cancer	0.0109	0.0201	CcSEcCtD
Ezogabine—UGT1A1—Estrogen metabolism—CYP3A4—bone cancer	0.0105	0.0227	CbGpPWpGaD
Ezogabine—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.0105	0.0227	CbGpPWpGaD
Ezogabine—Dysarthria—Cisplatin—bone cancer	0.00965	0.0179	CcSEcCtD
Ezogabine—UGT1A3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00957	0.0208	CbGpPWpGaD
Ezogabine—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00888	0.0193	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.00859	0.0186	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00859	0.0186	CbGpPWpGaD
Ezogabine—Encephalopathy—Methotrexate—bone cancer	0.0078	0.0145	CcSEcCtD
Ezogabine—Aphasia—Methotrexate—bone cancer	0.00772	0.0143	CcSEcCtD
Ezogabine—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.00743	0.0161	CbGpPWpGaD
Ezogabine—NAT2—Phase II conjugation—GSTP1—bone cancer	0.00724	0.0157	CbGpPWpGaD
Ezogabine—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00714	0.0155	CbGpPWpGaD
Ezogabine—Amnesia—Cisplatin—bone cancer	0.00705	0.0131	CcSEcCtD
Ezogabine—Hypokinesia—Epirubicin—bone cancer	0.00694	0.0129	CcSEcCtD
Ezogabine—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00661	0.0143	CbGpPWpGaD
Ezogabine—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00661	0.0143	CbGpPWpGaD
Ezogabine—Nystagmus—Epirubicin—bone cancer	0.00656	0.0122	CcSEcCtD
Ezogabine—Hypokinesia—Doxorubicin—bone cancer	0.00643	0.0119	CcSEcCtD
Ezogabine—Nystagmus—Doxorubicin—bone cancer	0.00607	0.0113	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.00587	0.0127	CbGpPWpGaD
Ezogabine—Skin discolouration—Methotrexate—bone cancer	0.00555	0.0103	CcSEcCtD
Ezogabine—Dysarthria—Methotrexate—bone cancer	0.0053	0.00983	CcSEcCtD
Ezogabine—Skin discolouration—Epirubicin—bone cancer	0.00519	0.00963	CcSEcCtD
Ezogabine—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.0051	0.0111	CbGpPWpGaD
Ezogabine—Dysarthria—Epirubicin—bone cancer	0.00496	0.0092	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—CYP3A4—bone cancer	0.00495	0.0107	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—CYP3A4—bone cancer	0.00488	0.0106	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.00484	0.0105	CbGpPWpGaD
Ezogabine—Hepatobiliary disease—Cisplatin—bone cancer	0.00483	0.00896	CcSEcCtD
Ezogabine—Gait disturbance—Epirubicin—bone cancer	0.0048	0.00891	CcSEcCtD
Ezogabine—Skin discolouration—Doxorubicin—bone cancer	0.0048	0.00891	CcSEcCtD
Ezogabine—Coordination abnormal—Epirubicin—bone cancer	0.00477	0.00886	CcSEcCtD
Ezogabine—Dysarthria—Doxorubicin—bone cancer	0.00459	0.00851	CcSEcCtD
Ezogabine—Coma—Methotrexate—bone cancer	0.00458	0.00849	CcSEcCtD
Ezogabine—Urinary tract disorder—Cisplatin—bone cancer	0.00453	0.0084	CcSEcCtD
Ezogabine—Urethral disorder—Cisplatin—bone cancer	0.00449	0.00834	CcSEcCtD
Ezogabine—Gait disturbance—Doxorubicin—bone cancer	0.00444	0.00825	CcSEcCtD
Ezogabine—Visual impairment—Cisplatin—bone cancer	0.00442	0.0082	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—bone cancer	0.00442	0.0082	CcSEcCtD
Ezogabine—UGT1A4—Phase II conjugation—GSTP1—bone cancer	0.00438	0.00951	CbGpPWpGaD
Ezogabine—Eye disorder—Cisplatin—bone cancer	0.00428	0.00795	CcSEcCtD
Ezogabine—Coma—Epirubicin—bone cancer	0.00428	0.00795	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—GSTP1—bone cancer	0.00423	0.00918	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—GSTP1—bone cancer	0.00418	0.00906	CbGpPWpGaD
Ezogabine—Alopecia—Cisplatin—bone cancer	0.00405	0.00752	CcSEcCtD
Ezogabine—Malnutrition—Cisplatin—bone cancer	0.00399	0.0074	CcSEcCtD
Ezogabine—Coma—Doxorubicin—bone cancer	0.00396	0.00735	CcSEcCtD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.00393	0.00853	CbGpPWpGaD
Ezogabine—Muscle spasms—Cisplatin—bone cancer	0.00384	0.00712	CcSEcCtD
Ezogabine—Vision blurred—Cisplatin—bone cancer	0.00376	0.00698	CcSEcCtD
Ezogabine—Tremor—Cisplatin—bone cancer	0.00374	0.00694	CcSEcCtD
Ezogabine—Ill-defined disorder—Cisplatin—bone cancer	0.0037	0.00687	CcSEcCtD
Ezogabine—UGT1A3—Phase II conjugation—GSTP1—bone cancer	0.00364	0.0079	CbGpPWpGaD
Ezogabine—Osteoarthritis—Methotrexate—bone cancer	0.00364	0.00675	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—bone cancer	0.00362	0.00672	CcSEcCtD
Ezogabine—Malaise—Cisplatin—bone cancer	0.0036	0.00668	CcSEcCtD
Ezogabine—Leukopenia—Cisplatin—bone cancer	0.00357	0.00663	CcSEcCtD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.00355	0.00769	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00344	0.00746	CbGpPWpGaD
Ezogabine—Diplopia—Epirubicin—bone cancer	0.0034	0.00631	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—bone cancer	0.0034	0.00631	CcSEcCtD
Ezogabine—Anxiety—Cisplatin—bone cancer	0.00339	0.00628	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—bone cancer	0.00336	0.00623	CcSEcCtD
Ezogabine—Discomfort—Cisplatin—bone cancer	0.00336	0.00623	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—bone cancer	0.00335	0.00622	CcSEcCtD
Ezogabine—Infection—Cisplatin—bone cancer	0.00324	0.006	CcSEcCtD
Ezogabine—KCNQ4—Neuronal System—BRAF—bone cancer	0.00321	0.00696	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—BRAF—bone cancer	0.00321	0.00696	CbGpPWpGaD
Ezogabine—Nervous system disorder—Cisplatin—bone cancer	0.00319	0.00593	CcSEcCtD
Ezogabine—Thrombocytopenia—Cisplatin—bone cancer	0.00319	0.00592	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—bone cancer	0.00315	0.00584	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—bone cancer	0.00315	0.00584	CcSEcCtD
Ezogabine—Hyperhidrosis—Cisplatin—bone cancer	0.00315	0.00584	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—bone cancer	0.00314	0.00583	CcSEcCtD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00308	0.00669	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00304	0.0066	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP3A4—bone cancer	0.003	0.0065	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NDUFA12—bone cancer	0.00297	0.00644	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP3A4—bone cancer	0.00296	0.00642	CbGpPWpGaD
Ezogabine—Influenza—Epirubicin—bone cancer	0.00294	0.00546	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—bone cancer	0.00294	0.00546	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—bone cancer	0.00294	0.00545	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—bone cancer	0.00294	0.00545	CcSEcCtD
Ezogabine—Paraesthesia—Cisplatin—bone cancer	0.00292	0.00543	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—GSTP1—bone cancer	0.00292	0.00634	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—TGFBR2—bone cancer	0.00292	0.00634	CbGpPWpGaD
Ezogabine—Liver function test abnormal—Doxorubicin—bone cancer	0.00291	0.00539	CcSEcCtD
Ezogabine—Dyspnoea—Cisplatin—bone cancer	0.0029	0.00539	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00286	0.0062	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00281	0.00522	CcSEcCtD
Ezogabine—Infestation—Methotrexate—bone cancer	0.0028	0.0052	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—bone cancer	0.0028	0.0052	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—bone cancer	0.00275	0.0051	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—bone cancer	0.00275	0.0051	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—bone cancer	0.00272	0.00505	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—bone cancer	0.00272	0.00505	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00271	0.00587	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—MDM2—bone cancer	0.00269	0.00583	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—MDM2—bone cancer	0.00269	0.00583	CbGpPWpGaD
Ezogabine—Feeling abnormal—Cisplatin—bone cancer	0.00268	0.00498	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—bone cancer	0.00268	0.00497	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—bone cancer	0.00267	0.00496	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—bone cancer	0.00265	0.00492	CcSEcCtD
Ezogabine—Infestation—Epirubicin—bone cancer	0.00262	0.00487	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—bone cancer	0.00262	0.00487	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—GSTP1—bone cancer	0.00256	0.00556	CbGpPWpGaD
Ezogabine—Neutropenia—Doxorubicin—bone cancer	0.00254	0.00472	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—bone cancer	0.00254	0.00472	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—GSTP1—bone cancer	0.00253	0.00549	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—GSTP1—bone cancer	0.00252	0.00546	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—GSTP1—bone cancer	0.00252	0.00546	CbGpPWpGaD
Ezogabine—Haematuria—Epirubicin—bone cancer	0.0025	0.00464	CcSEcCtD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.0025	0.00542	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP3A4—bone cancer	0.00249	0.00541	CbGpPWpGaD
Ezogabine—Urinary tract disorder—Methotrexate—bone cancer	0.00248	0.00461	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—bone cancer	0.00248	0.0046	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—bone cancer	0.00248	0.0046	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—bone cancer	0.00247	0.00458	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP3A4—bone cancer	0.00246	0.00533	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NT5C3A—bone cancer	0.00246	0.00533	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFBR2—bone cancer	0.00243	0.00527	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—GSTP1—bone cancer	0.00243	0.00527	CbGpPWpGaD
Ezogabine—Infestation NOS—Doxorubicin—bone cancer	0.00243	0.0045	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—bone cancer	0.00243	0.0045	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—bone cancer	0.00242	0.0045	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—bone cancer	0.00235	0.00436	CcSEcCtD
Ezogabine—Asthenia—Cisplatin—bone cancer	0.00234	0.00434	CcSEcCtD
Ezogabine—KCNQ3—L1CAM interactions—EGFR—bone cancer	0.00233	0.00505	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—EGFR—bone cancer	0.00233	0.00505	CbGpPWpGaD
Ezogabine—Urinary tract disorder—Epirubicin—bone cancer	0.00232	0.00431	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—bone cancer	0.00232	0.0043	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—bone cancer	0.00231	0.00429	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—bone cancer	0.00231	0.00428	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—bone cancer	0.00229	0.00426	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—bone cancer	0.00227	0.00421	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00225	0.00488	CbGpPWpGaD
Ezogabine—Alopecia—Methotrexate—bone cancer	0.00222	0.00412	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—bone cancer	0.0022	0.00409	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—bone cancer	0.0022	0.00408	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—bone cancer	0.00219	0.00406	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—bone cancer	0.00215	0.00399	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—bone cancer	0.00215	0.00398	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—bone cancer	0.00214	0.00396	CcSEcCtD
Ezogabine—UGT1A3—Biological oxidations—GSTP1—bone cancer	0.00213	0.00462	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—GSTP1—bone cancer	0.0021	0.00456	CbGpPWpGaD
Ezogabine—Visual impairment—Doxorubicin—bone cancer	0.0021	0.00389	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—bone cancer	0.00208	0.00386	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—bone cancer	0.00206	0.00383	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—bone cancer	0.00206	0.00383	CcSEcCtD
Ezogabine—Rash—Cisplatin—bone cancer	0.00205	0.00381	CcSEcCtD
Ezogabine—Dermatitis—Cisplatin—bone cancer	0.00205	0.00381	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—bone cancer	0.00205	0.0038	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—bone cancer	0.00204	0.00378	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—bone cancer	0.00203	0.00377	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00198	0.00429	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00198	0.00429	CbGpPWpGaD
Ezogabine—Malaise—Methotrexate—bone cancer	0.00197	0.00366	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—bone cancer	0.00197	0.00366	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—bone cancer	0.00197	0.00365	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—bone cancer	0.00196	0.00364	CcSEcCtD
Ezogabine—Nausea—Cisplatin—bone cancer	0.00193	0.00359	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—bone cancer	0.00193	0.00358	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—bone cancer	0.00192	0.00357	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—bone cancer	0.00191	0.00354	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—bone cancer	0.0019	0.00353	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—bone cancer	0.0019	0.00352	CcSEcCtD
Ezogabine—Malaise—Epirubicin—bone cancer	0.00185	0.00343	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—bone cancer	0.00184	0.00342	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—bone cancer	0.00184	0.00342	CcSEcCtD
Ezogabine—Syncope—Epirubicin—bone cancer	0.00184	0.00341	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—bone cancer	0.00183	0.0034	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—bone cancer	0.00182	0.00338	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—bone cancer	0.0018	0.00334	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—bone cancer	0.0018	0.00334	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—NDUFA12—bone cancer	0.0018	0.0039	CbGpPWpGaD
Ezogabine—Vision blurred—Doxorubicin—bone cancer	0.00179	0.00332	CcSEcCtD
Ezogabine—Infection—Methotrexate—bone cancer	0.00178	0.00329	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—bone cancer	0.00176	0.00326	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—bone cancer	0.00175	0.00325	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—bone cancer	0.00175	0.00325	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—bone cancer	0.00174	0.00323	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—MET—bone cancer	0.00174	0.00377	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MET—bone cancer	0.00174	0.00377	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—BRAF—bone cancer	0.00173	0.00376	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—BRAF—bone cancer	0.00173	0.00376	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Methotrexate—bone cancer	0.00173	0.00321	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—bone cancer	0.00172	0.0032	CcSEcCtD
Ezogabine—UGT1A1—Biological oxidations—CYP3A4—bone cancer	0.00172	0.00374	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP3A4—bone cancer	0.00172	0.00374	CbGpPWpGaD
Ezogabine—Malaise—Doxorubicin—bone cancer	0.00171	0.00317	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—bone cancer	0.00171	0.00317	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—bone cancer	0.0017	0.00316	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—bone cancer	0.0017	0.00316	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.0017	0.00368	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	0.0017	0.00368	CbGpPWpGaD
Ezogabine—Leukopenia—Doxorubicin—bone cancer	0.0017	0.00315	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—bone cancer	0.00169	0.00313	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.00168	0.00364	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.00168	0.00364	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	0.00168	0.00364	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSTP1—bone cancer	0.00168	0.00364	CbGpPWpGaD
Ezogabine—Loss of consciousness—Doxorubicin—bone cancer	0.00167	0.00309	CcSEcCtD
Ezogabine—Infection—Epirubicin—bone cancer	0.00166	0.00308	CcSEcCtD
Ezogabine—Shock—Epirubicin—bone cancer	0.00165	0.00305	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—bone cancer	0.00164	0.00304	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—bone cancer	0.00164	0.00304	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—bone cancer	0.00162	0.003	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—bone cancer	0.00161	0.00299	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—bone cancer	0.0016	0.00298	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—bone cancer	0.0016	0.00296	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—bone cancer	0.00159	0.00296	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—bone cancer	0.00159	0.00295	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—bone cancer	0.00158	0.00293	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—bone cancer	0.00157	0.00292	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—bone cancer	0.00156	0.0029	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00155	0.00337	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00155	0.00337	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00154	0.00286	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—bone cancer	0.00154	0.00286	CcSEcCtD
Ezogabine—Infection—Doxorubicin—bone cancer	0.00154	0.00285	CcSEcCtD
Ezogabine—Shock—Doxorubicin—bone cancer	0.00152	0.00283	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—bone cancer	0.00152	0.00282	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—bone cancer	0.00152	0.00281	CcSEcCtD
Ezogabine—Paraesthesia—Epirubicin—bone cancer	0.0015	0.00279	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—bone cancer	0.0015	0.00278	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—NDUFA12—bone cancer	0.00149	0.00324	CbGpPWpGaD
Ezogabine—Dyspnoea—Epirubicin—bone cancer	0.00149	0.00277	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—NT5C3A—bone cancer	0.00149	0.00323	CbGpPWpGaD
Ezogabine—Somnolence—Epirubicin—bone cancer	0.00149	0.00276	CcSEcCtD
Ezogabine—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.00147	0.0032	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTP1—bone cancer	0.00147	0.0032	CbGpPWpGaD
Ezogabine—Feeling abnormal—Methotrexate—bone cancer	0.00147	0.00273	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—bone cancer	0.00147	0.00273	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.00145	0.00315	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	0.00145	0.00315	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—MDM2—bone cancer	0.00145	0.00315	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—MDM2—bone cancer	0.00145	0.00315	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP2—bone cancer	0.00145	0.00315	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP2—bone cancer	0.00145	0.00315	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00144	0.00268	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—bone cancer	0.00144	0.00268	CcSEcCtD
Ezogabine—Constipation—Epirubicin—bone cancer	0.00143	0.00265	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—bone cancer	0.00139	0.00258	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—bone cancer	0.00138	0.00256	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—bone cancer	0.00138	0.00256	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—bone cancer	0.00138	0.00255	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—bone cancer	0.00136	0.00253	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00134	0.00248	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—bone cancer	0.00133	0.00248	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.00133	0.00288	CbGpPWpGaD
Ezogabine—Constipation—Doxorubicin—bone cancer	0.00132	0.00246	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.00131	0.00285	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.00129	0.00281	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.00129	0.00281	CbGpPWpGaD
Ezogabine—Asthenia—Methotrexate—bone cancer	0.00128	0.00238	CcSEcCtD
Ezogabine—Feeling abnormal—Doxorubicin—bone cancer	0.00128	0.00237	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—MET—bone cancer	0.00124	0.00269	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CDK4—bone cancer	0.00124	0.00269	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MET—bone cancer	0.00124	0.00269	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CDK4—bone cancer	0.00124	0.00269	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NT5C3A—bone cancer	0.00124	0.00269	CbGpPWpGaD
Ezogabine—Asthenia—Epirubicin—bone cancer	0.0012	0.00223	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—bone cancer	0.00118	0.00219	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.00114	0.00246	CbGpPWpGaD
Ezogabine—Rash—Methotrexate—bone cancer	0.00113	0.00209	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—bone cancer	0.00113	0.00209	CcSEcCtD
Ezogabine—Asthenia—Doxorubicin—bone cancer	0.00111	0.00206	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—bone cancer	0.00111	0.00205	CcSEcCtD
Ezogabine—KCNQ3—Axon guidance—MMP9—bone cancer	0.00109	0.00236	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—bone cancer	0.00109	0.00236	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ENO2—bone cancer	0.00108	0.00234	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—bone cancer	0.00106	0.00197	CcSEcCtD
Ezogabine—Rash—Epirubicin—bone cancer	0.00105	0.00196	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—bone cancer	0.00105	0.00195	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—MMP2—bone cancer	0.00103	0.00224	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP2—bone cancer	0.00103	0.00224	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NDUFA12—bone cancer	0.00103	0.00224	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NDUFA12—bone cancer	0.00103	0.00224	CbGpPWpGaD
Ezogabine—Dizziness—Doxorubicin—bone cancer	0.00102	0.0019	CcSEcCtD
Ezogabine—NAT2—Metabolism—DHFR—bone cancer	0.000999	0.00217	CbGpPWpGaD
Ezogabine—Nausea—Epirubicin—bone cancer	0.000993	0.00184	CcSEcCtD
Ezogabine—Rash—Doxorubicin—bone cancer	0.000976	0.00181	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—bone cancer	0.000975	0.00181	CcSEcCtD
Ezogabine—NAT2—Metabolism—GNA11—bone cancer	0.000934	0.00203	CbGpPWpGaD
Ezogabine—Nausea—Doxorubicin—bone cancer	0.000919	0.00171	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—EGFR—bone cancer	0.000881	0.00191	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—bone cancer	0.000881	0.00191	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NT5C3A—bone cancer	0.000855	0.00186	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NT5C3A—bone cancer	0.000855	0.00186	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP3A4—bone cancer	0.000846	0.00184	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NDUFA12—bone cancer	0.000796	0.00173	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—bone cancer	0.000778	0.00169	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—bone cancer	0.000778	0.00169	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTP1—bone cancer	0.000724	0.00157	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NT5C3A—bone cancer	0.000659	0.00143	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ENO2—bone cancer	0.000652	0.00142	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—bone cancer	0.000628	0.00136	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—bone cancer	0.000628	0.00136	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—DHFR—bone cancer	0.000605	0.00131	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GNA11—bone cancer	0.000566	0.00123	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ENO2—bone cancer	0.000542	0.00118	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP3A4—bone cancer	0.000513	0.00111	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—DHFR—bone cancer	0.000503	0.00109	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GNA11—bone cancer	0.00047	0.00102	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTP1—bone cancer	0.000439	0.000951	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP3A4—bone cancer	0.000426	0.000925	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—bone cancer	0.000375	0.000813	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ENO2—bone cancer	0.000375	0.000813	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ENO2—bone cancer	0.000375	0.000813	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTP1—bone cancer	0.000365	0.000791	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—DHFR—bone cancer	0.000348	0.000754	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—DHFR—bone cancer	0.000348	0.000754	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GNA11—bone cancer	0.000325	0.000705	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GNA11—bone cancer	0.000325	0.000705	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP3A4—bone cancer	0.000295	0.000639	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP3A4—bone cancer	0.000295	0.000639	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000293	0.000636	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ENO2—bone cancer	0.000289	0.000627	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—DHFR—bone cancer	0.000268	0.000581	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTP1—bone cancer	0.000252	0.000546	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTP1—bone cancer	0.000252	0.000546	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GNA11—bone cancer	0.00025	0.000543	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—bone cancer	0.000227	0.000493	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP3A4—bone cancer	0.000227	0.000492	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTP1—bone cancer	0.000194	0.000421	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—bone cancer	0.000189	0.00041	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—bone cancer	0.000131	0.000283	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—bone cancer	0.000131	0.000283	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—bone cancer	0.000101	0.000218	CbGpPWpGaD
